Ana C Z Gelatti - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Lung Cancer (Amsterdam, Netherlands)|October 1, 2019

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)Ana C Z Gelatti, Alexander Drilon, Fernando C Santini

Clinical Lung Cancer|May 12, 2020

Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung CancerAna C Z Gelatti, Vladmir C Cordeiro de Lima, Helano Freitas, et al.

JCO Global Oncology|June 24, 2026

Treatment of ALK+ Non-Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)Eldsamira Mascarenhas, Ana C Z Gelatti, Tatiane Montella, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Lung Cancer (Amsterdam, Netherlands)|October 1, 2019

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)Ana C Z Gelatti, Alexander Drilon, Fernando C Santini

Clinical Lung Cancer|May 12, 2020

Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung CancerAna C Z Gelatti, Vladmir C Cordeiro de Lima, Helano Freitas, et al.

JCO Global Oncology|June 24, 2026

Treatment of ALK+ Non-Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)Eldsamira Mascarenhas, Ana C Z Gelatti, Tatiane Montella, et al.

Pageof 1